Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
All fact checks
AI analysis

Fact check

“The FDA’s acceptance phase sometimes takes longer than the statutory 180‑day deadline.”
UnverifiableConfidence: LOW

Reasoning

The provided evidence cites a lawsuit and specific timeline (application submitted Sep 25, 2024; accepted Aug 12, 2025) showing the acceptance phase took 321 days, well beyond the 180‑day limit. Another excerpt confirms the FDA has never complied with the 180‑day deadline, supporting the claim.

On confidence: Multiple excerpts from a reputable secondary source directly state that the FDA's acceptance phase often exceeds the 180‑day statutory deadline and provide a concrete example of a 321‑day delay.

Important context

The claim pertains to the FDA's acceptance phase for new tobacco product applications, not the entire review process. The evidence references the 2021 Final Rule and a specific case involving Helix's flavored nicotine pouch applications.

Evidence

Supporting (2)

Limitations

The evidence is limited to a single secondary reporting source (Reason.com) and focuses on tobacco product applications; broader FDA acceptance timelines for other product categories are not addressed. No independent origin corroborated this claim, so it cannot be verified and confidence cannot be high.

Last verified:
Oct 1, 2026, 4:41 AM CDT
Pipeline:
2.1.0
Claim type:
Factual

Where this claim appeared

The FDA Promises To Streamline the Dauntingly Complex Rules for Approving Nicotine Products

Reason · Jacob Sullum